Skip to content
2024
SYSTEMIC DELIVERY, LOCAL ACTIVITY

Press Releases

Bonum Therapeutics to Present Posters and a Short Talk on its Novel Platform for Generating Conditionally Activated Targeted Therapies at Keystone Conference

“We are excited about the success of our platform technology with multiple conditionally active target/effector combinations, and we are particularly encouraged by the rapid progress of our lead program, conditionally active cLAG3-IL2”

Bonum Therapeutics to Present Lead Program at AACR

“We are excited with the progress of our lead program, cLAG3-IL2, and are eager to make the first public presentation about the program at AACR.”

Good Therapeutics Announces Acquisition of Conditionally Active PD-1-Regulated IL-2 Program by Roche

“Given Roche’s expertise in this field and broad capabilities in oncology, we believe they are a perfect choice for taking this important program forward…”

In the news

Sorry, no posts matched your criteria.

Also seen in

Sorry, no posts matched your criteria.

Blog

A BD Checklist: Best Practices for Partnering with Pharma

Throughout my 25+ years in industry, whether I am advising startups or mentoring individuals interested in career transitions to business development, I am often asked about my approach to deal making.  Here I share some best practices for biotechs looking to partner an asset with pharma.  I still use this approach to make better decisions under pressure and to set realistic goals for deals, most recently as Chief Business Officer at Good Therapeutics from 2021 – 2022, where I co-led the successful completion of Good’s sale to Roche for $250 million plus deal-comparable milestones – one of the largest deals of 2022 for a preclinical asset.

Blog

Should My Biotech Startup Buy Or Produce The Proteins We Use?

I joined Good Therapeutics (now Bonum Therapeutics) in the summer of 2021. This was a marvelous opportunity to develop a new class of regulated cytokine therapeutics for cancer and autoimmune diseases. My prime directive was to build a team focused on protein production and characterization, with an aim to select stable “manufacturable” leads to move into clinical development.

Blog

Developing the Next Generation of Targeted, Conditionally Active Cytokine Therapeutics

Four years ago, I joined Bonum Therapeutics’ predecessor, Good Therapeutics, fascinated by the mechanistic concept developed by Founder and CEO John Mulligan. He envisioned an antibody-cytokine fusion protein, or immunocytokine, wherein the cytokine was selectively active when the antibody portion was bound to its target. This idea was appealing, as it would potentially allow the creation of cytokine therapeutics with conditional activity on specific cell types and populations. Immune agonists, including cytokines, have held particular interest for me throughout my career in cancer immunotherapy, and I’ve come to appreciate the unique challenges associated with their utilization.

Blog

6 Tips for Successful Drug Discovery Teamwork

In my two previous articles, I’ve discussed the need to think about the big picture in drug research and development, as well as considerations that can improve one’s chances for success at the bench level. Overall, however, science is a team effort. And while people don’t always think about the choreography of good scientific teamwork, there are factors that should be considered and skills that can be developed to increase a drug discovery team’s overall effectiveness and chance of success.

Blog
2024
SYSTEMIC DELIVERY, LOCAL ACTIVITY

Press Releases

Bonum Therapeutics to Present Posters and a Short Talk on its Novel Platform for Generating Conditionally Activated Targeted Therapies at Keystone Conference

“We are excited about the success of our platform technology with multiple conditionally active target/effector combinations, and we are particularly encouraged by the rapid progress of our lead program, conditionally active cLAG3-IL2”

Bonum Therapeutics to Present Lead Program at AACR

“We are excited with the progress of our lead program, cLAG3-IL2, and are eager to make the first public presentation about the program at AACR.”

Good Therapeutics Announces Acquisition of Conditionally Active PD-1-Regulated IL-2 Program by Roche

“Given Roche’s expertise in this field and broad capabilities in oncology, we believe they are a perfect choice for taking this important program forward…”

In the news

Sorry, no posts matched your criteria.

Also seen in

Sorry, no posts matched your criteria.

Blog

A BD Checklist: Best Practices for Partnering with Pharma

Throughout my 25+ years in industry, whether I am advising startups or mentoring individuals interested in career transitions to business development, I am often asked about my approach to deal making.  Here I share some best practices for biotechs looking to partner an asset with pharma.  I still use this approach to make better decisions under pressure and to set realistic goals for deals, most recently as Chief Business Officer at Good Therapeutics from 2021 – 2022, where I co-led the successful completion of Good’s sale to Roche for $250 million plus deal-comparable milestones – one of the largest deals of 2022 for a preclinical asset.

Blog

Should My Biotech Startup Buy Or Produce The Proteins We Use?

I joined Good Therapeutics (now Bonum Therapeutics) in the summer of 2021. This was a marvelous opportunity to develop a new class of regulated cytokine therapeutics for cancer and autoimmune diseases. My prime directive was to build a team focused on protein production and characterization, with an aim to select stable “manufacturable” leads to move into clinical development.

Blog

Developing the Next Generation of Targeted, Conditionally Active Cytokine Therapeutics

Four years ago, I joined Bonum Therapeutics’ predecessor, Good Therapeutics, fascinated by the mechanistic concept developed by Founder and CEO John Mulligan. He envisioned an antibody-cytokine fusion protein, or immunocytokine, wherein the cytokine was selectively active when the antibody portion was bound to its target. This idea was appealing, as it would potentially allow the creation of cytokine therapeutics with conditional activity on specific cell types and populations. Immune agonists, including cytokines, have held particular interest for me throughout my career in cancer immunotherapy, and I’ve come to appreciate the unique challenges associated with their utilization.

Blog

6 Tips for Successful Drug Discovery Teamwork

In my two previous articles, I’ve discussed the need to think about the big picture in drug research and development, as well as considerations that can improve one’s chances for success at the bench level. Overall, however, science is a team effort. And while people don’t always think about the choreography of good scientific teamwork, there are factors that should be considered and skills that can be developed to increase a drug discovery team’s overall effectiveness and chance of success.

Blog
2024
SYSTEMIC DELIVERY, LOCAL ACTIVITY

Press Releases

Bonum Therapeutics to Present Posters and a Short Talk on its Novel Platform for Generating Conditionally Activated Targeted Therapies at Keystone Conference

“We are excited about the success of our platform technology with multiple conditionally active target/effector combinations, and we are particularly encouraged by the rapid progress of our lead program, conditionally active cLAG3-IL2”

Bonum Therapeutics to Present Lead Program at AACR

“We are excited with the progress of our lead program, cLAG3-IL2, and are eager to make the first public presentation about the program at AACR.”

Good Therapeutics Announces Acquisition of Conditionally Active PD-1-Regulated IL-2 Program by Roche

“Given Roche’s expertise in this field and broad capabilities in oncology, we believe they are a perfect choice for taking this important program forward…”

In the news

Sorry, no posts matched your criteria.

Also seen in

Sorry, no posts matched your criteria.

Blog

A BD Checklist: Best Practices for Partnering with Pharma

Throughout my 25+ years in industry, whether I am advising startups or mentoring individuals interested in career transitions to business development, I am often asked about my approach to deal making.  Here I share some best practices for biotechs looking to partner an asset with pharma.  I still use this approach to make better decisions under pressure and to set realistic goals for deals, most recently as Chief Business Officer at Good Therapeutics from 2021 – 2022, where I co-led the successful completion of Good’s sale to Roche for $250 million plus deal-comparable milestones – one of the largest deals of 2022 for a preclinical asset.

Blog

Should My Biotech Startup Buy Or Produce The Proteins We Use?

I joined Good Therapeutics (now Bonum Therapeutics) in the summer of 2021. This was a marvelous opportunity to develop a new class of regulated cytokine therapeutics for cancer and autoimmune diseases. My prime directive was to build a team focused on protein production and characterization, with an aim to select stable “manufacturable” leads to move into clinical development.

Blog

Developing the Next Generation of Targeted, Conditionally Active Cytokine Therapeutics

Four years ago, I joined Bonum Therapeutics’ predecessor, Good Therapeutics, fascinated by the mechanistic concept developed by Founder and CEO John Mulligan. He envisioned an antibody-cytokine fusion protein, or immunocytokine, wherein the cytokine was selectively active when the antibody portion was bound to its target. This idea was appealing, as it would potentially allow the creation of cytokine therapeutics with conditional activity on specific cell types and populations. Immune agonists, including cytokines, have held particular interest for me throughout my career in cancer immunotherapy, and I’ve come to appreciate the unique challenges associated with their utilization.

Blog

6 Tips for Successful Drug Discovery Teamwork

In my two previous articles, I’ve discussed the need to think about the big picture in drug research and development, as well as considerations that can improve one’s chances for success at the bench level. Overall, however, science is a team effort. And while people don’t always think about the choreography of good scientific teamwork, there are factors that should be considered and skills that can be developed to increase a drug discovery team’s overall effectiveness and chance of success.

Blog